Literature DB >> 29964121

Should DTPA, an Aminocarboxylic acid (ethylenediamine-based) chelating agent, be considered a developmental toxicant?

Josje Arts1, Steffen Bade2, Marta Badrinas3, Nicholas Ball4, Stuart Hindle4.   

Abstract

Aminocarboxylic acid (ethylenediamine-based) chelating agents, such as DTPA and EDTA, are widely used in a variety of products and processes. Recently the European RAC proposed to classify DTPA as a developmental toxicant Category 1B according to CLP. This paper provides unequivocal and significant evidence that developmental effects cannot be considered an intrinsic property of the chelating substances themselves since: (1) animals fed a zinc deficient diet during gestation exhibit developmental toxicity of a similar nature and severity to that observed in studies involving such chelates, (2) sufficient supplementation of zinc in the diet, or administration of zinc bound chelates, completely negates the developmental effects. Moreover, the bioavailability of DTPA is very low with >95% of oral doses excreted unchanged via the feces within 24 h. If DTPA would possess the intrinsic property to be developmentally toxic, simple zinc supplementation should not be sufficient to negate these effects. Furthermore, the relevance of classification is highly questionable since worker or consumer exposure could not lead to a scenario whereby sufficient zinc deficiency would manifest itself. Therefore classification of DTPA for such effects is not protective of human health; instead it leads to onerous and disproportionate restrictions being placed on this substance.
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bioavailability; Chelating agents; Developmental toxicity; Zinc depletion

Mesh:

Substances:

Year:  2018        PMID: 29964121     DOI: 10.1016/j.yrtph.2018.06.019

Source DB:  PubMed          Journal:  Regul Toxicol Pharmacol        ISSN: 0273-2300            Impact factor:   3.271


  1 in total

1.  Cationic zinc is required for factor XII recruitment and activation by stimulated platelets and for thrombus formation in vivo.

Authors:  Sharjeel A Chaudhry; Matthew Serrata; Lindsay Tomczak; Sarah Higgins; Justine Ryu; Dylan Laprise; Keiichi Enjyoji; Roelof Bekendam; Virendar Kaushik; Robert Flaumenhaft; Pavan K Bendapudi
Journal:  J Thromb Haemost       Date:  2020-07-30       Impact factor: 5.824

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.